Form D · Biotechnology

BioEclipse Therapeutics, Inc.

South San Francisco, CA · CIK 0001780708

Offering snapshot reported Oct 10, 2019 · SEC filing

Reported sold: $10.1M
Investors reported: 13
Minimum accepted: $0
First sale: Jun 7, 2019

Fundraising history

Reported sold

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

Reported sold$7,768,257 → $10,126,014
Reported investors10 → 13

Filing history

Scroll to see all columns →

Filed	Filing type	Reported sold	Change vs linked filing	Investors	Source
Oct 10, 2019	Amendment	$10,126,014	$2,357,757vs Jun 25, 2019	13	SEC filing
Jun 25, 2019	Initial	$7,768,257	No comparison	10	SEC filing

Offering details

Securities: Equity, Option to acquire
Exemptions: 06b
Duration over one year: No
Business combination: No

Sales commissions: $0
Finders' fees: $132K
Form D file number: 021-342724

Sales compensation recipients

Scroll to see all columns →

Recipient	CRD	Associated broker-dealer
Venture.co Brokerage Services LLC	173924

Source: Form D, filed Oct 10, 2019. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
Name	Reported role
Elona Baum	Director
Benjamin Carter	Executive
Pamela Contag	Director, Executive
Mark Frohlich	Director
Biao He	Director
Pamela Reilly Contag	Director, Executive
Gregory Schiffman	Director
Catherine Sohn	Director
Stephen Thau	Executive

Issuer details

Industry: Biotechnology (See others in industry)

Address:

329 Oyster Point Blvd., 3 Rd Floor
South San Francisco, CA, 94080